RT Journal Article
SR Electronic
T1 The focus and timing of COVID-19 pandemic control measures under healthcare resource constraints
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.16.20067611
DO 10.1101/2020.04.16.20067611
A1 Wei, Chen
A1 Wang, Zhengyang
A1 Liang, Zhichao
A1 Liu, Quanying
YR 2020
UL http://medrxiv.org/content/early/2020/04/19/2020.04.16.20067611.abstract
AB Generalizing COVID-19 control strategies in one community to others is confounded by community’s unique demographic and socioeconomic attributes. Here we propose a tailored dynamic model accounting for community-specific transmission controls and medical resource availability. We trained the model using data from Wuhan and applied it to other countries. We show that isolating suspected cases is most effective in reducing transmission rate if the intervention starts early. Having more hospital beds provides leverage that diminishes with delayed intervention onset. The importance of transmission control in turn increases by 65% with a 7-day delay. Furthermore, prolonging outbreak duration by applying an intermediate, rather than strict, transmission control would not prevent hospital overload regardless of bed capacity, and would likely result in a high ratio (21% ∼ 84%) of the population being infected but not treated. The model could help different countries design control policies and gauge the severity of suppression failure.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by Guangdong Natural Science Foundation Joint Fund [No. 2019A1515111038] and High-level University Fund [No. G02386301, G02386401].Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets generated during and/or analysed during the current study as well as the code used are available from the corresponding author on reasonable request.